Format

Send to

Choose Destination
Eur J Med Chem. 2011 Nov;46(11):5435-42. doi: 10.1016/j.ejmech.2011.09.001. Epub 2011 Sep 8.

Exploiting the lipoic acid structure in the search for novel multitarget ligands against Alzheimer's disease.

Author information

1
Department of Pharmaceutical Sciences, University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy. michela.rosini@unibo.it

Abstract

Lipoic acid (LA) is a natural antioxidant. Its structure was previously combined with that of the acetylcholinesterase inhibitor tacrine to give lipocrine (1), a lead compound multitargeted against Alzheimer's disease (AD). Herein, we further explore LA as a privileged structure for developing multimodal compounds to investigate AD. First, we studied the effect of LA chirality by evaluating the cholinesterase profile of 1's enantiomers. Then, a new series of LA hybrids was designed and synthesized by combining racemic LA with motifs of other known anticholinesterase agents (rivastigmine and memoquin). This afforded 4, which represents a step forward in the search for balanced anticholinesterase and antioxidant capacities.

PMID:
21924801
DOI:
10.1016/j.ejmech.2011.09.001
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center